Related Experiment Video
Updated: Nov 23, 2025
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
Novelty and nuance in the intensive care unit: new options to combat multidrug resistant pneumonia
Andrew F Shorr1, Marya D Zilberberg2
1Pulmonary and Critical Care Medicine Section (AFS), Medstar Washington Hospital Center, Washington, DC.
Purpose Of Review:
To describe the increasing burden of multidrug resistant (MDR) Gram-negative pathogens in severe pneumonia and to examine the clinical trials supporting a role for novel agents for the treatment of this infection.
Recent Findings:
MDR Gram-negative bacteria cause an increasing proportion of severe pneumonias. Although the epidemiology of resistance varies across the globe, all regions have seen an evolution in resistance, especially among Enterobacterales spp, Pseudomonas aeruginosa, and Acinetobacter bumannii. Fortunately, several clinical trials have established the role for multiple new antibiotics in pneumonia. Although these drugs all have different ranges of in vitro activity and potency, each helps to address the problem of MDR. These studies have varied based on the proportion of subjects undergoing mechanical ventilation and the comparator agents employed. Although all these trials have demonstrated noninferiority to the comparator, the mortality rates across the analyses ranged from <% to >20%. None of the recent investigations included immunocompromised subjects.
Summary:
Multiple new agents exist for treating MDR Gram-negative pneumonia. These agents are not interchangeable. Thus, one must approach their adoption with a nuanced eye.
Insights
The growing threat of multidrug-resistant (MDR) Gram-negative bacteria in severe pneumonia is being addressed by new antibiotics. Clinical trials show these novel agents are effective, but careful selection is crucial for treatment success.
Area of Science:
- Infectious Diseases
- Pulmonology
- Microbiology
Background:
- Increasing prevalence of multidrug-resistant (MDR) Gram-negative pathogens in severe pneumonia cases globally.
- Specific pathogens like Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii show evolving resistance patterns.
- Severe pneumonia poses a significant and growing health burden worldwide.
Purpose of the Study:
- To detail the escalating challenge posed by MDR Gram-negative pathogens in severe pneumonia.
- To review clinical trials evaluating new antimicrobial agents for treating this infection.
- To understand the evolving landscape of Gram-negative resistance in respiratory infections.
Main Methods:
- Systematic review of recent clinical trials on novel antibiotic agents for Gram-negative pneumonia.
- Analysis of trial data regarding efficacy, in vitro activity, and patient populations.
- Examination of resistance epidemiology across different geographical regions.
Main Results:
- Several new antibiotic classes have demonstrated efficacy in clinical trials for MDR Gram-negative pneumonia.
- While non-inferiority was shown, mortality rates in trials varied significantly (from <1% to >20%).
- Recent trials did not include immunocompromised patient populations, a key limitation.
Conclusions:
- New agents are available for treating MDR Gram-negative pneumonia, offering valuable therapeutic options.
- These novel antibiotics are not interchangeable and require a nuanced approach to clinical application.
- Further research is needed to address treatment in immunocompromised individuals and optimize agent selection.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:30Pneumonia III: Complications and Assessment
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...